Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Newly-developed antidotes for dabigatran and rivaroxaban show promise

  • Print
  • Comment
  • Save

For the first time, an antidote developed specifically for dabigatran successfully reversed its anticoagulant effect in healthy volunteers, according to research presented at this week’s American Heart Association’s Scientific Sessions.

It follows a study published earlier this year that showed giving prothrombin complex concentrate to healthy subjects could reverse the effects of rivaroxaban but not dabigatran.

The new study is from researchers who have developed an antibody fragment that specifically binds dabigatran and prevents it from inhibiting clot formation.

It was given as 1 hour or 5-minute infusions to 145 healthy male volunteers and immediate, complete and sustained reversal of dabigatran-induced anticoagulation was seen.

Although the new oral anticoagulants (NOACs) haver distinct advantages over warfarin because they can be prescribed in fixed doses and do not require frequent monitoring, there have been worries about how to stop their anticoagulant effect in patients suffering a major bleed or undergoing emergency surgery.

But the researchers warn the new antidotes are still under development and not yet approved for clinical use.

Read more here

 

 

Have your say

  • Print
  • Comment
  • Save